DNA minor groove binding agents

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Minor groove binding agents are molecules able to interact with the minor groove of DNA and to covalently bind residues lying in this groove. A common characteristic of this class of anticancer agents is their peculiar mechanism of action. In fact, the majority of them have a mechanism of action very distinct from that of the classic major groove DNA interacting agents and more in common with that of classic anticancer agents used in the clinic. Minor groove binding agents are characterized by potent antitumor activity in vitro and in vivo. One of the major limitations in their clinical use has been the potent and often unexpected myelotoxicity which prevents using potentially active doses. Many efforts have been made in the past to synthesize new minor groove binding agents retaining high antitumor activity and an acceptable toxicity profile. Molecules such as brostallicin and trabectedin represent clear examples of minor groove binding agents with relatively moderate undesired effects which are now in clinical evaluation. The peculiar mechanism of interaction of brostallicin with glutathione and glutathione-S-transferase, and the peculiar interaction of trabectedin with the nucleotide excision repair system, make these molecules particularly attractive for combination studies with classic anticancer agents with which synergism has been described at preclinical levels. Based on the interesting features of these new molecules, studies on minor groove DNA binding agents are still warranted and either natural or synthetic compounds are continuously being evaluated for their antitumor properties.

Original languageEnglish
Pages (from-to)301-309
Number of pages9
JournalDrugs of the Future
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 2005

Fingerprint

trabectedin
Antineoplastic Agents
DNA
Glutathione Transferase
DNA Repair
Glutathione
brostallicin

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Pharmacology

Cite this

DNA minor groove binding agents. / Damia, Giovanna; Broggini, Massimo.

In: Drugs of the Future, Vol. 30, No. 3, 03.2005, p. 301-309.

Research output: Contribution to journalArticle

@article{f0f4f8fe8ab94b98ac9f15a5bc6cea93,
title = "DNA minor groove binding agents",
abstract = "Minor groove binding agents are molecules able to interact with the minor groove of DNA and to covalently bind residues lying in this groove. A common characteristic of this class of anticancer agents is their peculiar mechanism of action. In fact, the majority of them have a mechanism of action very distinct from that of the classic major groove DNA interacting agents and more in common with that of classic anticancer agents used in the clinic. Minor groove binding agents are characterized by potent antitumor activity in vitro and in vivo. One of the major limitations in their clinical use has been the potent and often unexpected myelotoxicity which prevents using potentially active doses. Many efforts have been made in the past to synthesize new minor groove binding agents retaining high antitumor activity and an acceptable toxicity profile. Molecules such as brostallicin and trabectedin represent clear examples of minor groove binding agents with relatively moderate undesired effects which are now in clinical evaluation. The peculiar mechanism of interaction of brostallicin with glutathione and glutathione-S-transferase, and the peculiar interaction of trabectedin with the nucleotide excision repair system, make these molecules particularly attractive for combination studies with classic anticancer agents with which synergism has been described at preclinical levels. Based on the interesting features of these new molecules, studies on minor groove DNA binding agents are still warranted and either natural or synthetic compounds are continuously being evaluated for their antitumor properties.",
author = "Giovanna Damia and Massimo Broggini",
year = "2005",
month = "3",
doi = "10.1358/dof.2005.030.03.878168",
language = "English",
volume = "30",
pages = "301--309",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "3",

}

TY - JOUR

T1 - DNA minor groove binding agents

AU - Damia, Giovanna

AU - Broggini, Massimo

PY - 2005/3

Y1 - 2005/3

N2 - Minor groove binding agents are molecules able to interact with the minor groove of DNA and to covalently bind residues lying in this groove. A common characteristic of this class of anticancer agents is their peculiar mechanism of action. In fact, the majority of them have a mechanism of action very distinct from that of the classic major groove DNA interacting agents and more in common with that of classic anticancer agents used in the clinic. Minor groove binding agents are characterized by potent antitumor activity in vitro and in vivo. One of the major limitations in their clinical use has been the potent and often unexpected myelotoxicity which prevents using potentially active doses. Many efforts have been made in the past to synthesize new minor groove binding agents retaining high antitumor activity and an acceptable toxicity profile. Molecules such as brostallicin and trabectedin represent clear examples of minor groove binding agents with relatively moderate undesired effects which are now in clinical evaluation. The peculiar mechanism of interaction of brostallicin with glutathione and glutathione-S-transferase, and the peculiar interaction of trabectedin with the nucleotide excision repair system, make these molecules particularly attractive for combination studies with classic anticancer agents with which synergism has been described at preclinical levels. Based on the interesting features of these new molecules, studies on minor groove DNA binding agents are still warranted and either natural or synthetic compounds are continuously being evaluated for their antitumor properties.

AB - Minor groove binding agents are molecules able to interact with the minor groove of DNA and to covalently bind residues lying in this groove. A common characteristic of this class of anticancer agents is their peculiar mechanism of action. In fact, the majority of them have a mechanism of action very distinct from that of the classic major groove DNA interacting agents and more in common with that of classic anticancer agents used in the clinic. Minor groove binding agents are characterized by potent antitumor activity in vitro and in vivo. One of the major limitations in their clinical use has been the potent and often unexpected myelotoxicity which prevents using potentially active doses. Many efforts have been made in the past to synthesize new minor groove binding agents retaining high antitumor activity and an acceptable toxicity profile. Molecules such as brostallicin and trabectedin represent clear examples of minor groove binding agents with relatively moderate undesired effects which are now in clinical evaluation. The peculiar mechanism of interaction of brostallicin with glutathione and glutathione-S-transferase, and the peculiar interaction of trabectedin with the nucleotide excision repair system, make these molecules particularly attractive for combination studies with classic anticancer agents with which synergism has been described at preclinical levels. Based on the interesting features of these new molecules, studies on minor groove DNA binding agents are still warranted and either natural or synthetic compounds are continuously being evaluated for their antitumor properties.

UR - http://www.scopus.com/inward/record.url?scp=18844431095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844431095&partnerID=8YFLogxK

U2 - 10.1358/dof.2005.030.03.878168

DO - 10.1358/dof.2005.030.03.878168

M3 - Article

VL - 30

SP - 301

EP - 309

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 3

ER -